Co-Authors
This is a "connection" page, showing publications co-authored by JANET TU and GEORGE R BLUMENSCHEIN.
Connection Strength
0.526
-
Identifying MAGE-A4-positive tumors for TCR T?cell therapies in HLA-A*02-eligible patients. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101265.
Score: 0.241
-
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na?ve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2024 Oct 08; JCO2400533.
Score: 0.062
-
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2024 Jul 04; 15(1):5621.
Score: 0.061
-
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693.
Score: 0.056
-
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391.
Score: 0.053
-
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.
Score: 0.052